92 204

Cited 4 times in

The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancer

DC FieldValueLanguage
dc.contributor.author김주항-
dc.contributor.author조병철-
dc.date.accessioned2015-04-23T16:20:18Z-
dc.date.available2015-04-23T16:20:18Z-
dc.date.issued2010-
dc.identifier.issn0513-5796-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/100402-
dc.description.abstractThe strategies of incorporating monoclonal antibodies (MoABs) have now proved efficacy in the first-line treatment of advanced non-small cell lung cancer (NSCLC). These include targeting the vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR). Bevacizumab is a MoAB targeting the vascular endothelial growth factor (VEGF), an important mediator of new blood vessel formation. Cetuximab is a MoAB directed at EGFR. Binding cetuximab to EGFR blocks signal transduction and promotes receptor internalization and degradation. In this review, we present current data of bevacizumab and cetuximab for the first line treatment of advanced NSCLC. We also refer to their potential for Asian patients with advanced NSCLC in the first-line setting.-
dc.description.statementOfResponsibilityopen-
dc.format.extent1~8-
dc.relation.isPartOfYONSEI MEDICAL JOURNAL-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAntibodies, Monoclonal/therapeutic use*-
dc.subject.MESHAntibodies, Monoclonal, Humanized-
dc.subject.MESHAntineoplastic Agents/therapeutic use*-
dc.subject.MESHAsian Continental Ancestry Group-
dc.subject.MESHBevacizumab-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/drug therapy*-
dc.subject.MESHCetuximab-
dc.subject.MESHHumans-
dc.titleThe role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorByoung Chul Cho-
dc.contributor.googleauthorJoo Hang Kim-
dc.contributor.googleauthorRoss A Soo-
dc.contributor.googleauthorChih-Hsin Yang-
dc.identifier.doi10.3349/ymj.2010.51.1.1-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00945-
dc.contributor.localIdA03822-
dc.relation.journalcodeJ02813-
dc.identifier.eissn1976-2437-
dc.identifier.pmid20046507-
dc.subject.keywordNon-small cell lung cancer-
dc.subject.keywordbevacizumab-
dc.subject.keywordcetuximab-
dc.subject.keywordchemotherapy-
dc.subject.keywordmonoclonal antibody-
dc.contributor.alternativeNameKim, Joo Hang-
dc.contributor.alternativeNameCho, Byoung Chul-
dc.contributor.affiliatedAuthorKim, Joo Hang-
dc.contributor.affiliatedAuthorCho, Byoung Chul-
dc.citation.volume51-
dc.citation.number1-
dc.citation.startPage1-
dc.citation.endPage8-
dc.identifier.bibliographicCitationYONSEI MEDICAL JOURNAL, Vol.51(1) : 1-8, 2010-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.